摘要
因为许多恶性肿瘤以opn过度表达为特点,所以骨桥蛋白(opn)基因的调控因子是过度表达基因靶向疗法具有吸引力的代表。检测到肿瘤细胞的最大opn启动子(Popn)调控强度与阳性对照转染一样强(102.69%)。同时,肿瘤细胞系的Popn-驱动报告表达减少到90%。同时,在非癌肿瘤细胞系报告Popn-驱动表达减少至90%。922 bp大小的opn启动子的缺失突变分析结果与已报到的上游转录起始点的922碱基不一致。启动子序列单核苷酸多态性(SNPs) 能够进一步增强靶向作用和表达。研究发现SNPs -443C、 -155GG 、-66T t片段会导致癌细胞的Popn-驱动转染增加(增长1.23 ~ 3.48倍),同时伴随着正常对照组报告蛋白表达的减少(变化0.69倍)。进一步的研究证实内源性opn mRNA水平与Popn-驱动报告表达之间缺乏令人惊奇的关联性(R2=0.24)。然而,顾及opn mRNA剪接变异体,则不同的opn-a mRNA水平和P opn-驱动转基因活性之间显示很强的负相关。这些数据对靶向表达启动子今后研究产生影响。
关键词: 选择性剪接,靶向表达,基因传递,SNP,SPP1
Current Gene Therapy
Title:The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy
Volume: 15 Issue: 1
Author(s): X.G. Chen and W.T. Godbey
Affiliation:
关键词: 选择性剪接,靶向表达,基因传递,SNP,SPP1
摘要: Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Export Options
About this article
Cite this article as:
X.G. Chen and W.T. Godbey , The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127094033
DOI https://dx.doi.org/10.2174/1566523214666141127094033 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Vascular Homing Peptides with Cell-Penetrating Properties
Current Pharmaceutical Design Development of New ELISA with High Sensitivity and Selectivity for Bioanalysis of Bevacizumab: A Monoclonal Antibody Used for Cancer Immunotherapy
Current Analytical Chemistry Pore-Forming Proteins and their Application in Biotechnology
Current Pharmaceutical Biotechnology The Modulation of Inter-Organelle Cross-Talk to Control Apoptosis
Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology The Evolution of Vibration Sonoelastography
Current Medical Imaging Meet Our Editorial Board Member
Current Chemical Biology Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology A Novel Method to Synthesize 4-Aryl-1H-1,2,3-Triazoles and its Antihepatoma Activity
Anti-Cancer Agents in Medicinal Chemistry Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention
Current Cancer Drug Targets Synthesis and Antitumor Activity of Novel N-Benzoyl-N'-substituted Pyrimidinyl (Thio)semicarbazide Derivatives
Letters in Drug Design & Discovery Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Preface
Current Cancer Therapy Reviews Editorial (Thematic Issue: Study and Prediction of Pharmacokinetic Drug-Drug Interactions)
Current Drug Metabolism From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Current Topics in Medicinal Chemistry Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Episcopic 3D Imaging Methods: Tools for Researching Gene Function
Current Genomics Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design